CVS, Cigna and UnitedHealth
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Zacks.com on MSN2h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...
Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback